Table 2.
Univariate Cox regression analyses for overall survival and relapse-free survival in ovarian carcinomas
| Characteristics | No. | OS | RFS | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| Overall ovarian carcinomas (n = 104) | ||||||
| Age, y, ≥ 60 (vs < 60) | 33/104 | 2.686 (1.535-4.698) | <0.001 | 2.157 (1.299-3.582) | 0.003 | |
| Stage, III & IV (vs I & II) | 52/104 | 3.579 (1.917-6.681) | <0.001 | 3.930 (2.245-6.878) | <0.001 | |
| Tumor size, cm, > 10 (vs ≤ 10) | 36/104 | 0.524 (0.274-1.004) | 0.051 | 0.649 (0.375-1.125) | 0.123 | |
| LN metastasis, presence (vs absence) | 20/104 | 1.568 (0.831-2.959) | 0.165 | 1.889 (1.076-3.314) | 0.027 | |
| Ascites, presence (vs absence) | 33/104 | 1.997 (1.140-3.498) | 0.016 | 1.854 (1.116-3.077) | 0.017 | |
| Bilaterality, bilateral (vs unilateral) | 45/104 | 1.647 (0.943-2.876) | 0.080 | 1.995 (1.204-3.303) | 0.007 | |
| CA19-9, elevated (vs normal) | 17/83 | 0.753 (0.314-1.806) | 0.525 | 0.811 (0.379-1.733) | 0.588 | |
| CA125, elevated (vs normal) | 75/93 | 4.451 (1.376-14.393) | 0.013 | 4.458 (1.609-12.351) | 0.004 | |
| Histologic grade, high (vs low) | 77/104 | 3.762 (1.491-9.496) | 0.005 | 3.794 (1.719-8.374) | <0.001 | |
| DBC1, positive (vs negative) | 66/104 | 3.474 (1.684-7.166) | <0.001 | 3.007 (1.624-5.567) | <0.001 | |
| BRCA1, positive (vs negative) | 46/104 | 2.263 (1.287-3.979) | 0.005 | 2.254 (1.359-3.739) | 0.002 | |
| Serous carcinomas (n = 75) | ||||||
| Age, y, ≥ 60 (vs < 60) | 30/75 | 2.601 (1.411-4.796) | 0.002 | 1.926 (1.116-3.323) | 0.019 | |
| Stage, III & IV (vs I & II) | 46/75 | 2.263 (1.131-4.528) | 0.021 | 2.809 (1.485-5.312) | 0.001 | |
| Tumor size, cm, > 10 (vs ≤ 10) | 19/75 | 0.625 (0.289-1.352) | 0.233 | 0.817 (0.436-1.532) | 0.529 | |
| LN metastasis, presence (vs absence) | 19/75 | 1.200 (0.613-2.349) | 0.595 | 1.502 (0.831-2.714) | 0.178 | |
| Ascites, presence (vs absence) | 30/75 | 1.793 (0.977-3.291) | 0.060 | 1.645 (0.953-2.839) | 0.074 | |
| Bilaterality, bilateral (vs unilateral) | 41/75 | 1.200 (0.647-2.224) | 0.563 | 1.423 (0.813-2.492) | 0.217 | |
| CA19-9, elevated (vs normal) | 8/58 | 0.679 (0.206-2.236) | 0.524 | 1.086 (0.425-2.773) | 0.863 | |
| CA125, elevated (vs normal) | 61/68 | 2.898 (0.697-12.056) | 0.144 | 2.152 (0.668-6.931) | 0.199 | |
| Histologic grade, high (vs low) | 63/75 | 4.401 (1.061-18.260) | 0.041 | 4.341 (1.347-13.990) | 0.014 | |
| DBC1, positive (vs negative) | 54/75 | 4.277 (1.674-10.926) | 0.002 | 2.811 (1.363-5.794) | 0.005 | |
| BRCA1, positive (vs negative) | 36/75 | 1.861 (1.007-3.438) | 0.047 | 1.792 (1.032-3.110) | 0.038 | |
| High-grade serous carcinomas (n = 63) | ||||||
| Age, y, ≥ 60 (vs < 60) | 27/63 | 2.090 (1.119-3.900) | 0.021 | 1.591 (0.907-2.791) | 0.105 | |
| Stage, III & IV (vs I & II) | 38/63 | 2.188 (1.080-4.434) | 0.030 | 2.811 (1.464-5.399) | 0.002 | |
| Tumor size, cm, > 10 (vs ≤ 10) | 15/63 | 0.736 (0.339-1.599) | 0.439 | 0.860 (0.448-1.651) | 0.650 | |
| LN metastasis, presence (vs absence) | 15/63 | 1.520 (0.766-3.017) | 0.232 | 1.841 (0.992-3.417) | 0.053 | |
| Ascites, presence (vs absence) | 26/63 | 1.395 (0.749-2.598) | 0.294 | 1.340 (0.764-2.351) | 0.308 | |
| Bilaterality, bilateral (vs unilateral) | 36/63 | 1.300 (0.683-2.475) | 0.424 | 1.452 (0.809--2.603) | 0.211 | |
| CA19-9, elevated (vs normal) | 6/49 | 0.726 (0.220-2.403) | 0.600 | 1.344 (0.521-3.467) | 0.541 | |
| CA125, elevated (vs normal) | 53/58 | 2.220 (0.531-9.276) | 0.275 | 1.443 (0.446-4.672) | 0.540 | |
| DBC1, positive (vs negative) | 50/63 | 4.031 (1.427-11.382) | 0.008 | 2.540 (1.135-5.684) | 0.023 | |
| BRCA1, positive (vs negative) | 32/63 | 2.010 (1.063-3.803) | 0.032 | 1.719 (0.973-3.038) | 0.062 | |